beh et s like syndrome associated with psoriasis lichen sclerosus and variant in nf b1

Original title: “Behçet's-Like Syndrome Associated With Psoriasis, Lichen Sclerosus and Variant in NF-κB1.”

effectiveness and safety of spesolimab in adolescents and adults with generalized pustular psoriasis

Original title: “Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.”

il 17 at the eye joint interface in psoriatic disease mechanisms clinical correlates and therapeutic implications

Original title: “IL-17 at the eye - joint interface in psoriatic disease: mechanisms, clinical correlates, and therapeutic implications.”

efficacy and safety of janus kinase and tyk2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis a systematic review

Original title: “Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.”

inflammation triggered nanodrug delivery microneedles targeting pathogenic cox2 endothelial cell mediated glycocalyx degradation to ameliorate psoriasis

Original title: “Inflammation-triggered nanodrug delivery microneedles targeting pathogenic COX2(+) endothelial cell-mediated glycocalyx degradation to ameliorate psoriasis.”

Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.

Original title: “Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial”

early onset renal amyloidosis associated with psoriasis in a child with cryopyrinopathy a case report

Original title: “Early-onset renal amyloidosis associated with psoriasis in a child with cryopyrinopathy: a case report.”

phenotype dependent effects of il 17a inhibitors on lipid profiles in moderate to severe plaque psoriasis a retrospective cohort study

Original title: “Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study.”

national psoriasis foundation primer on glp 1 receptor agonists in psoriasis a review

Original title: “The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review.”

A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to be dosed less frequently.

Original title: “Oruka surges as long-acting psoriasis drug shows early promise”

uncommon coexistence of mid borderline leprosy and generalized pustular psoriasis

Original title: “The Uncommon Coexistence of Mid-Borderline Leprosy and Generalized Pustular Psoriasis.”

update on the etiology and pathogenesis of erythrodermic psoriasis

Original title: “Update on the Etiology and Pathogenesis of Erythrodermic Psoriasis.”

Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a new psoriasis drug. Plus, Aurinia Pharmaceuticals gets a new C-suite, FDA releases draft guidance on non-animal models and the CDC’s vaccine advisory committee is not being disbanded after all.

Original title: “Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More”

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in sales.

Original title: “J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections”

joint assessment matters diagnostic and therapeutic benefits of interdisciplinary psoriasis care

Original title: “Joint Assessment Matters: Diagnostic and Therapeutic Benefits of Interdisciplinary Psoriasis Care.”

Dec 18, 2025 Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) Dec 17, 2025 Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis · Dec 5, 2025 Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies ... Dec 18, 2025 Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) Dec 17, 2025 Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis · Dec 5, 2025 Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad Investors may focus on timely FLASH2 execution, regulatory interactions, and future trial designs as key checkpoints for the rare-disease strategy. cutaneous t-cell lymphoma, investigator-initiated study, area under the curve (auc), dermatology life quality index, +1 more ... "clinical trial for HyBryte™ ... in the treatment of early-stage cutaneous T-cell lymphoma (CTCL)" With 2026 being an important year for us, we remain energized by the promise of our late-stage rare disease pipeline as we continue to evaluate potential strategic options, including, but not limited to, partnership and merger and acquisition opportunities. The previously publicly disclosed upcoming key clinical events and milestones are summarized below. Top-line results from the actively enrolling 80 patient confirmatory Phase 3 FLASH2 ( ... Hypericin 2) clinical trial for HyBryte™ (SGX301 or synthetic hypericin) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL) are expected in the second half of 2026, with an interim analysis fast approaching in 2Q. FLASH2 interim readout in 2Q and top-line CTCL data in 2H 2026 lead Soligenix update, with Behçet's, psoriasis progress and funding runway through 2026.

Original title: “Rare cancer therapy: Soligenix targets ~$2B in potential annual sales”

temporomandibular joint ankylosis associated with psoriasis and familial mediterranean fever a rare case report

Original title: “Temporomandibular Joint Ankylosis Associated with Psoriasis and Familial Mediterranean Fever: A Rare Case Report.”